Welcome to our dedicated page for Pulmonx SEC filings (Ticker: LUNG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Pulmonx's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Pulmonx's regulatory disclosures and financial reporting.
Pulmonx Corp (LUNG) reported that President and CEO, and director, Glendon E. French III sold a total of 41,882 shares of common stock on September 1, 2026 at $2.26 per share in transactions described as sales to cover tax withholding obligations arising from the vesting of Restricted Stock Units granted on March 1, 2023 and December 1, 2025. A footnote also notes the acquisition of 1,656 shares under Pulmonx’s 2020 Employee Stock Purchase Plan on August 14, 2026, and French is reported as indirectly holding 918,198 shares of common stock through a family trust for which he and his spouse serve as trustees and beneficiaries. No Rule 10b5-1 trading plan is reported for these transactions.
Pulmonx Corp (LUNG) reported that Chief Science & Technology Officer Radhakrishnan Srikanth sold an aggregate of 14,245 shares of common stock on September 1, 2026 at $2.26 per share. The filing states each sale was made to cover tax withholding obligations arising from vesting of Restricted Stock Units granted between March 2023 and March 2026. No Rule 10b5-1 trading plan is indicated, and post-transaction share holdings are not reported in this filing.
Pulmonx Corp (LUNG) reported that its General Counsel, David Aaron Lehman, sold an aggregate 14,334 shares of Common Stock on September 1, 2026 at $2.26 per share in four open-market or private transactions. Footnotes state that each sale covered tax withholding obligations arising from the vesting of Restricted Stock Units granted in 2023, 2024, 2025, and 2026, and no Rule 10b5-1 trading plan is reported.
Pulmonx Corp (LUNG) reported that Chief Commercial Officer Rose Geoffrey Beran sold a total of 7,879 shares of common stock on September 1, 2026, in four open-market transactions at $2.26 per share. Footnotes state each sale was made to cover tax withholding obligations arising from the vesting of Restricted Stock Units granted in 2023, 2024, 2025, and 2026. No Rule 10b5-1 trading plan is reported.
Morgan Stanley and Morgan Stanley Capital Services LLC report their beneficial ownership of Pulmonx Corp common stock on an amended Schedule 13G. Morgan Stanley reports 2,920,241 shares beneficially owned, representing 6.9% of the common stock, with 0 shares held with sole voting or dispositive power and the position held with shared voting and dispositive power. Morgan Stanley Capital Services LLC reports 2,885,147 shares, representing 6.8%, all with shared voting and dispositive power and none with sole power. The ownership is attributed to specified Morgan Stanley reporting units, and does not include securities held by disaggregated operating units under SEC Release No. 34-39538.
Pulmonx Corporation, a commercial-stage medical technology company focused on minimally invasive treatments for severe emphysema, reported Q2 2026 revenue of $22.8 million, slightly below $23.9 million a year earlier. Gross margin improved to 78.0% from 72.1%.
Net loss narrowed to $10.1 million in Q2 2026 from $15.2 million in Q2 2025, and to $23.7 million for the first half of 2026 from $29.6 million a year prior. As of June 30, 2026, cash and cash equivalents were $55.8 million, with $37.5 million of term loans and credit agreements outstanding and an accumulated deficit of $545.3 million. Management states that existing cash resources are expected to support operations for at least the next 12 months.
During 2026 the company repaid its prior $37.0 million CIBC term loan and entered into a new senior secured facility with Perceptive for up to $60.0 million, drawing $40.0 million at closing and issuing equity warrants in connection with the financing.
Pulmonx Corporation reported second-quarter 2026 results with worldwide revenue of $22.8 million, a 5% year-over-year decline, including U.S. revenue of $14.2 million and international revenue of $8.6 million. International revenue excluding China grew 12% year over year.
Gross profit was $17.7 million, yielding a record 78% gross margin, up from 72% a year earlier. Operating expenses fell 16% to $26.8 million, helping reduce net loss to $10.1 million, or $0.24 per share, and cut Adjusted EBITDA loss to $5.1 million, a 39% reduction.
Cash and cash equivalents were $55.8 million as of June 30, 2026. For full-year 2026, the company continues to expect revenue of $90 million to $92 million, gross margin of about 76%, operating expenses of $109 million to $111 million, and an approximately $23 million decrease in cash, cash equivalents and marketable securities.
BlackRock, Inc. filed an amended Schedule 13G reporting its beneficial ownership of Pulmonx Corp common stock. BlackRock reports beneficial ownership of 765,721 shares of common stock, representing 1.8% of the class.
BlackRock has sole voting power and sole dispositive power over all 765,721 shares, with no shared voting or dispositive power. Various underlying clients have rights to dividends or sale proceeds, but no single client holds more than five percent of Pulmonx’s outstanding common shares.
Burns Thomas William reported acquisition or exercise transactions in this Form 4 filing.
Pulmonx Corp director Thomas William Burns received an equity grant in the form of restricted stock units. The award covers 40,000 shares of Pulmonx common stock at a stated price of $0.0000 per share, reflecting a compensation grant rather than a market purchase.
According to the terms, the restricted stock units vest on the earlier of the one-year anniversary of the June 5, 2026 grant date (or the next business day) or the date of the Annual Meeting of the Stockholders for the year after the grant. Following this grant, Burns directly holds 113,399 shares of Pulmonx common stock.
Ferrari Richard reported acquisition or exercise transactions in this Form 4 filing.
Pulmonx Corp director Richard Ferrari reported an equity award. He received 40,000 shares of common stock through a grant of Restricted Stock Units at a stated price of $0.00 per share. These RSUs vest on the earlier of the one-year anniversary of the June 5, 2026 grant date or the next annual stockholders’ meeting. Following this award, Ferrari directly holds 127,024 Pulmonx shares.